• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Personalizing cancer care with improved tumor models

Bioengineer by Bioengineer
January 21, 2021
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Bryan Welm

WASHINGTON, January 21, 2021 — Cancer is a major, worldwide challenge, and its impact is projected to escalate due to aging and growth of the population. Researchers recognize that new approaches to diagnose and treat deadly cancers, including identifying new drugs to treat cancer, will be essential to curbing the growing impact of the disease.

While decades of investment in research have resulted in substantial improvements in surviving cancer, a key challenge remains in identifying new drugs that improve outcomes for cancer patients, particularly for cancers when tumors have spread throughout the body.

In APL Bioengineering, by AIP Publishing, researchers suggest a major hurdle to identifying new drugs is the paucity of models — organisms mimicking human cancers in a lab setting — for cancer research that accurately represent patient tumors. They provide a perspective on strategies for developing models to inform cancer treatment using models from individual patients and where the field needs to go in terms of research in animal systems and in culture systems.

“In addition to having better models for cancer research, we are trying to evolve patient-derived models to the point where we can have speedy and reliable drug testing on patient specimens to help personalize cancer care,” said author Alana Welm. “This is the concept of functional precision oncology.”

In functional precision oncology, tumor samples from individual patients are tested for susceptibility to various drugs in the context of a patient-derived xenograft or culture system in order to guide patient therapy during the course of their disease.

The researchers suggest an even more powerful approach to accelerating the pace of cancer research would be to couple patient-derived model development with the plethora of clinical trials being run every day.

If clinical data and models were collated and shared along with drug response information, machine learning could facilitate analysis of this big data to discover complex patterns of drug response or resistance across individuals, which could then be further tested in the patient-derived models.

The researchers envision that patients’ tumors may be bioinformatically profiled to identify a complex set of features that can be used to predict response to various therapies and informed by functional drug response data collected from previous studies. The researchers believe this would facilitate selection of more effective drugs earlier in treatment, while preventing administration of toxic drugs that offer no benefit.

These types of data could even be integrated with germline DNA sequence variants that predict aberrant drug metabolism and toxicity for an even more personalized approach to reduce mortality from cancer while simultaneously reducing toxicity as much as possible.

###

The article “Towards improved models of human cancer” is authored by Bryan E. Welm, Christos Vaklavas, and Alana L. Welm. The article appears in APL Bioengineering (DOI: 10.1063/5.0030534) and can be accessed at https://aip.scitation.org/doi/10.1063/5.0030534.

See also: Combining best of both worlds for cancer modeling at https://publishing.aip.org/publications/latest-content/combining-best-of-both-worlds-for-cancer-modeling/

ABOUT THE JOURNAL

APL Bioengineering is an open access journal publishing significant discoveries specific to the understanding and advancement of physics and engineering of biological systems. See http://aip.scitation.org/journal/apb.

Media Contact
Larry Frum
[email protected]

Related Journal Article

http://dx.doi.org/10.1063/5.0030534

Tags: BiologyBiomechanics/BiophysicscancerCell BiologyChemistry/Physics/Materials SciencesMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Parkinson’s Biomarkers Assessed After Sublethal Gamma Radiation

October 3, 2025

MNDA Boosts Immunosuppression in Colorectal Cancer via PMN-MDSC

October 3, 2025

Marcus Kinetics Control Singlet, Triplet Oxygen Evolution

October 3, 2025

Physiologically Relevant Intermediate State of Potassium Channel

October 3, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    92 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    87 shares
    Share 35 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Parkinson’s Biomarkers Assessed After Sublethal Gamma Radiation

Genome Sequencing Uncovers Population Divergence in Yaks

MNDA Boosts Immunosuppression in Colorectal Cancer via PMN-MDSC

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.